Shots:
- Alteogen has granted AstraZeneca global rights of ALT-B4 to develop & commercialize SC formulations of multiple oncology assets, while Alteogen will be responsible for clinical & commercial supply of ALT-B4
- As per the deal, Alteogen will receive an upfront, along with development, regulatory, & sales milestones, plus royalties on sale of commercialized products
- ALT-B4, developed using Hybrozyme tech, is a human recombinant hyaluronidase enzyme that temporarily hydrolyzes hyaluronan in the extracellular matrix. This allows large-volume SC administration of drugs which are usually given via IV infusion
Ref: AstraZeneca | Image: AstraZeneca & Alteogen
Related News:- Daiichi Sankyo and AstraZeneca Dose the First Patient with Adjuvant Datroway in P-III (TROPION-Lung12) Trial for Adenocarcinoma NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
